Infensa Bioscience

About Infensa Bioscience

Infensa Bioscience is a pre-clinical stage biotechnology company, established in 2021, focused on developing first-in-class therapeutics to address the significant unmet medical need in treating stroke and heart attack. Headquartered in Brisbane, Australia, the company was spun out of the University of Queensland and is built upon foundational research from the university's Institute for Molecular Bioscience. The company's name itself is derived from *Hadronyche infensa*, the scientific name for the K'gari funnel-web spider, which is the source of its lead drug candidate.

The core of Infensa's work is a portfolio of peptide drugs, notably the lead compound IB001 (also referred to as Hi1a), which originates from spider venom. This molecule acts as a potent and selective inhibitor of the acid-sensing ion channel 1a (ASIC1a). This channel is a key mediator of cell death in the heart and brain when tissues become acidic due to a lack of oxygen during ischemic events like a heart attack or stroke. By blocking this pathway, Infensa's therapeutic aims to protect neurons and heart muscle cells from injury, potentially reducing long-term organ damage and improving patient outcomes. Preclinical studies have shown significant promise, with one of the company's lead molecules reducing brain damage by 80% in a model of human stroke.

Infensa Bioscience was co-founded by a team of researchers including CEO Associate Professor Mark Smythe, Professor Glenn King, and Associate Professor Nathan Palpant. Dr. Smythe brings over 30 years of experience in the biotech sector, having previously founded Protagonist Therapeutics. Professor King is also a seasoned entrepreneur, having founded Vestaron Corporation, and holds 15 patents. The company secured substantial initial funding, raising $15.6M (A$23 million) in a 2022 funding round to advance its lead candidate toward clinical trials. This funding was supported by investors including Australian Unity, Monash Investment Holdings, and The University of Queensland. The company's business model is centered on the clinical development and subsequent commercialization of its proprietary drug candidates, targeting a potential market of tens of millions of patients annually who suffer from heart attacks or strokes. With Investigational New Drug (IND) studies complete, Infensa is preparing to initiate Phase 1 clinical trials, aiming to attract partners and investors for the transition to Phase 2.